tiprankstipranks
Novavax (CH:NVAX)
NASDAQ:NVAX
Switzerland Market
NVAX
Novavax
RESEARCH TOOLSreports

Novavax (NVAX) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

NVAX Analyst Ratings

Hold
5Ratings
Hold
2 Buy
1 Hold
2 Sell
Based on 5 analysts giving stock ratings to
Novavax
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NVAX Stock 12 Month Forecast

Average Price Target

$9.50
Based on 5 Wall Street analysts offering 12 month price targets for Novavax in the last 3 months. The average price target is $9.50 with a high forecast of $15.30 and a low forecast of $5.64. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$15.30Average Price Target$9.50Lowest Price Target$5.64
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:NVAX
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF6.44
Sell
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (NASDAQ: LENZ), Novavax (NASDAQ: NVAX) and Beam Therapeutics (NASDAQ: BEAM)
BTIG Analyst forecast on CH:NVAX
Thomas Shrader
BTIG
BTIG
CHF15.3
Buy
―
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (NASDAQ: BMEA) and Novavax (NASDAQ: NVAX)
Citi Analyst forecast on CH:NVAX
Geoff Meacham
Citi
Citi
CHF5.64
Sell
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (NASDAQ: STTK), Novavax (NASDAQ: NVAX) and Airsculpt Technologies (NASDAQ: AIRS)
TD Cowen Analyst forecast on CH:NVAX
Steve Scala
TD Cowen
TD Cowen
CHF6.44→CHF7.25
Hold
―
Assigned
05/06/26
TD Cowen’s Steve Scala Maintains Hold on NVAX, Nudges Price Target Up Amid Improved Tolerability Data but Limited Real‑World Effectiveness Evidence
H.C. Wainwright Analyst forecast on CH:NVAX
Sean Lee CFA
H.C. Wainwright
H.C. Wainwright
CHF12.88
Buy
―
Reiterated
04/21/26
Novavax: COMPARE Study Underscores Safety Edge of Nuvaxovid and Supports Upside from Royalties, Milestones, and Licensing
B. Riley Securities Analyst forecast on CH:NVAX
Mayank Mamtani
B. Riley Securities
B. Riley Securities
CHF12.88→CHF14.49
Buy
―
Reiterated
04/09/26
Novavax price target raised to $18 from $16 at B. RileyNovavax price target raised to $18 from $16 at B. Riley
Cantor Fitzgerald Analyst forecast on CH:NVAX
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
CHF14.49
Buy
―
Reiterated
01/13/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on CH:NVAX
Anupam Rama
J.P. Morgan
J.P. Morgan
CHF5.64→CHF4.83
Sell
―
Reiterated
11/18/25
Novavax price target lowered to $6 from $7 at JPMorganNovavax price target lowered to $6 from $7 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:NVAX
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF6.44
Sell
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (NASDAQ: LENZ), Novavax (NASDAQ: NVAX) and Beam Therapeutics (NASDAQ: BEAM)
BTIG Analyst forecast on CH:NVAX
Thomas Shrader
BTIG
BTIG
CHF15.3
Buy
―
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (NASDAQ: BMEA) and Novavax (NASDAQ: NVAX)
Citi Analyst forecast on CH:NVAX
Geoff Meacham
Citi
Citi
CHF5.64
Sell
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (NASDAQ: STTK), Novavax (NASDAQ: NVAX) and Airsculpt Technologies (NASDAQ: AIRS)
TD Cowen Analyst forecast on CH:NVAX
Steve Scala
TD Cowen
TD Cowen
CHF6.44→CHF7.25
Hold
―
Assigned
05/06/26
TD Cowen’s Steve Scala Maintains Hold on NVAX, Nudges Price Target Up Amid Improved Tolerability Data but Limited Real‑World Effectiveness Evidence
H.C. Wainwright Analyst forecast on CH:NVAX
Sean Lee CFA
H.C. Wainwright
H.C. Wainwright
CHF12.88
Buy
―
Reiterated
04/21/26
Novavax: COMPARE Study Underscores Safety Edge of Nuvaxovid and Supports Upside from Royalties, Milestones, and Licensing
B. Riley Securities Analyst forecast on CH:NVAX
Mayank Mamtani
B. Riley Securities
B. Riley Securities
CHF12.88→CHF14.49
Buy
―
Reiterated
04/09/26
Novavax price target raised to $18 from $16 at B. RileyNovavax price target raised to $18 from $16 at B. Riley
Cantor Fitzgerald Analyst forecast on CH:NVAX
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
CHF14.49
Buy
―
Reiterated
01/13/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on CH:NVAX
Anupam Rama
J.P. Morgan
J.P. Morgan
CHF5.64→CHF4.83
Sell
―
Reiterated
11/18/25
Novavax price target lowered to $6 from $7 at JPMorganNovavax price target lowered to $6 from $7 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novavax

3 Months
Alec StranahanBank of America Securities
Success Rate
12/18 ratings generated profit
67%
Average Return
+12.51%
Copying Alec Stranahan's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +12.51% per trade.
1 Year
Alec StranahanBank of America Securities
Success Rate
6/18 ratings generated profit
33%
Average Return
+2.37%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +2.37% per trade.
2 Years
Alec StranahanBank of America Securities
Success Rate
6/18 ratings generated profit
33%
Average Return
-2.56%
Copying Alec Stranahan's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -2.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVAX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
3
2
3
1
Buy
1
0
0
0
0
Hold
1
1
1
1
1
Sell
10
5
2
2
2
Strong Sell
0
0
0
0
0
total
15
9
5
6
4
In the current month, NVAX has received 1 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. NVAX average Analyst price target in the past 3 months is 9.50.
Each month's total comprises the sum of three months' worth of ratings.

NVAX Financial Forecast

NVAX Earnings Forecast

Next quarter’s earnings estimate for NVAX is -$0.32 with a range of -$0.45 to -$0.20. The previous quarter’s EPS was -$0.05. NVAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year NVAX has Performed in-line its overall industry.
Next quarter’s earnings estimate for NVAX is -$0.32 with a range of -$0.45 to -$0.20. The previous quarter’s EPS was -$0.05. NVAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year NVAX has Performed in-line its overall industry.

NVAX Sales Forecast

Next quarter’s sales forecast for NVAX is $41.87M with a range of $28.15M to $64.50M. The previous quarter’s sales results were $112.20M. NVAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year NVAX has Performed in-line its overall industry.
Next quarter’s sales forecast for NVAX is $41.87M with a range of $28.15M to $64.50M. The previous quarter’s sales results were $112.20M. NVAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year NVAX has Performed in-line its overall industry.

NVAX Stock Forecast FAQ

What is CH:NVAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Novavax’s 12-month average price target is 9.50.
    What is CH:NVAX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:NVAX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Novavax a Buy, Sell or Hold?
        Novavax has a consensus rating of Hold, which is based on 2 buy ratings, 1 hold ratings and 2 sell ratings.
          What is Novavax’s share price target?
          The average share price target for Novavax is 9.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $15.30 ,and the lowest forecast is $5.64. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Novavax?
            Novavax’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
              How can I buy shares of Novavax?
              To buy shares of CH:NVAX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.